Current Status and Quality of Prognosis Prediction Models of Non-small Cell Lung Cancer Constructed Using Computed Tomography (CT)-based Radiomics: a Systematic Review and Radiomics Quality Score 2.0 Assessment

Overview

Journal Quant Imaging Med Surg

Specialty Radiology

Date 2024 Sep 16

PMID 39281123

Authors

Xiaoteng Jia

Yuhang Wang

Han Zhang

Daqiang Sun

Affiliations

Soon will be listed here.

Abstract

Background: Radiomics extracts specific quantitative data from medical images and explores the characteristics of tumors by analyzing these representations and making predictions. The purpose of this paper is to review computed tomography (CT)-based radiomics articles related to prognostic outcomes in non-small cell lung cancer (NSCLC), assess their scientificity and quality by the latest radiomics quality score (RQS) 2.0 scoring criteria, and provide references for subsequent related studies.

Methods: CT-based radiomics studies on NSCLC prognosis published from 1 November 2012 to 30 November 2022 in English were screened through the databases of the Cochrane Library, Embase, and PubMed. By excluding criteria such as non-original studies, small sample sizes studies, positron emission tomography (PET)/CT only, and methodological studies only, 17 studies in English were included. The RQS proposed in 2017 is a quality evaluation index specific to radiomics following the PRISMA guidelines, and the latest update of RQS 2.0 has improved the scientificity and completeness of the score. Each checkpoint either belongs to handcrafted radiomics (HCR), deep learning, or both.

Results: The 17 included studies covered most treatments for NSCLC, including radiotherapy, chemotherapy, surgery, radiofrequency ablation, immunotherapy, and targeted therapy, and predicted outcomes such as overall survival (OS), progression-free survival (PFS), distant metastases, and disease-free survival (DFS). The median score rate for the included studies was 28%, with a range of 12% to 44%. The quality of studies in HCR is not high, and only 4 studies have been validated with independent cohorts.

Conclusions: The value of radiomics studies needs to be increased, such that clinical application will be possible, and the field of radiomics still has much room for growth. To make prediction models more reliable and stable in forecasting the prognosis of NSCLC and advancing the individualized treatment of NSCLC patients, more clinicians must participate in their development and clinical testing.

References

Khorrami M, Jain P, Bera K, Alilou M, Thawani R, Patil P . Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features. Lung Cancer. 2019; 135:1-9. PMC: 6711393. DOI: 10.1016/j.lungcan.2019.06.020. View

Fried D, Tucker S, Zhou S, Liao Z, Mawlawi O, Ibbott G . Prognostic value and reproducibility of pretreatment CT texture features in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014; 90(4):834-42. PMC: 4349397. DOI: 10.1016/j.ijrobp.2014.07.020. View

He B, Zhong Y, Zhu Y, Deng J, Fang M, She Y . Deep learning for predicting immunotherapeutic efficacy in advanced non-small cell lung cancer patients: a retrospective study combining progression-free survival risk and overall survival risk. Transl Lung Cancer Res. 2022; 11(4):670-685. PMC: 9073735. DOI: 10.21037/tlcr-22-244. View

Song J, Shi J, Dong D, Fang M, Zhong W, Wang K . A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy. Clin Cancer Res. 2018; 24(15):3583-3592. DOI: 10.1158/1078-0432.CCR-17-2507. View

Hosny A, Parmar C, Coroller T, Grossmann P, Zeleznik R, Kumar A . Deep learning for lung cancer prognostication: A retrospective multi-cohort radiomics study. PLoS Med. 2018; 15(11):e1002711. PMC: 6269088. DOI: 10.1371/journal.pmed.1002711. View

Huang L, Chen J, Hu W, Xu X, Liu D, Wen J . Assessment of a Radiomic Signature Developed in a General NSCLC Cohort for Predicting Overall Survival of ALK-Positive Patients With Different Treatment Types. Clin Lung Cancer. 2019; 20(6):e638-e651. DOI: 10.1016/j.cllc.2019.05.005. View

Lambin P, Leijenaar R, Deist T, Peerlings J, de Jong E, van Timmeren J . Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017; 14(12):749-762. DOI: 10.1038/nrclinonc.2017.141. View

Bak S, Park H, Sohn I, Lee S, Ahn M, Lee H . Prognostic Impact of Longitudinal Monitoring of Radiomic Features in Patients with Advanced Non-Small Cell Lung Cancer. Sci Rep. 2019; 9(1):8730. PMC: 6584670. DOI: 10.1038/s41598-019-45117-y. View

Huang Y, Liu Z, He L, Chen X, Pan D, Ma Z . Radiomics Signature: A Potential Biomarker for the Prediction of Disease-Free Survival in Early-Stage (I or II) Non-Small Cell Lung Cancer. Radiology. 2016; 281(3):947-957. DOI: 10.1148/radiol.2016152234. View

10.

Passaro A, Brahmer J, Antonia S, Mok T, Peters S . Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies. J Clin Oncol. 2022; 40(6):598-610. DOI: 10.1200/JCO.21.01845. View

11.

Li Wen Y, Leech M . Review of the Role of Radiomics in Tumour Risk Classification and Prognosis of Cancer. Anticancer Res. 2020; 40(7):3605-3618. DOI: 10.21873/anticanres.14350. View

12.

Perez-Johnston R, Araujo-Filho J, Connolly J, Caso R, Whiting K, Tan K . CT-based Radiogenomic Analysis of Clinical Stage I Lung Adenocarcinoma with Histopathologic Features and Oncologic Outcomes. Radiology. 2022; 303(3):664-672. PMC: 9131171. DOI: 10.1148/radiol.211582. View

13.

Chang J, Senan S, Paul M, Mehran R, Louie A, Balter P . Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015; 16(6):630-7. PMC: 4489408. DOI: 10.1016/S1470-2045(15)70168-3. View

14.

Gillies R, Kinahan P, Hricak H . Radiomics: Images Are More than Pictures, They Are Data. Radiology. 2015; 278(2):563-77. PMC: 4734157. DOI: 10.1148/radiol.2015151169. View

15.

Sugai Y, Kadoya N, Tanaka S, Tanabe S, Umeda M, Yamamoto T . Impact of feature selection methods and subgroup factors on prognostic analysis with CT-based radiomics in non-small cell lung cancer patients. Radiat Oncol. 2021; 16(1):80. PMC: 8086112. DOI: 10.1186/s13014-021-01810-9. View

16.

Li H, Zhang R, Wang S, Fang M, Zhu Y, Hu Z . CT-Based Radiomic Signature as a Prognostic Factor in Stage IV -Positive Non-small-cell Lung Cancer Treated With TKI Crizotinib: A Proof-of-Concept Study. Front Oncol. 2020; 10:57. PMC: 7040202. DOI: 10.3389/fonc.2020.00057. View

17.

Fiz F, Vigano L, Gennaro N, Costa G, Bella L, Boichuk A . Radiomics of Liver Metastases: A Systematic Review. Cancers (Basel). 2020; 12(10). PMC: 7600822. DOI: 10.3390/cancers12102881. View

18.

Friedlaender A, Naidoo J, Banna G, Metro G, Forde P, Addeo A . Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC. Cancer Treat Rev. 2022; 104:102350. DOI: 10.1016/j.ctrv.2022.102350. View

19.

Ahn S, Park C, Park S, Kim H, Song C, Lee S . Prognostic value of computed tomography texture features in non-small cell lung cancers treated with definitive concomitant chemoradiotherapy. Invest Radiol. 2015; 50(10):719-25. DOI: 10.1097/RLI.0000000000000174. View

20.

Cheng J, Pan Y, Huang W, Huang K, Cui Y, Hong W . Differentiation between immune checkpoint inhibitor-related and radiation pneumonitis in lung cancer by CT radiomics and machine learning. Med Phys. 2022; 49(3):1547-1558. PMC: 9306809. DOI: 10.1002/mp.15451. View